DexCom, Inc. (NASDAQ:DXCM) has received a consensus rating of “Buy” from the seventeen analysts that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and twelve have given a buy rating to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $454.94.
Several brokerages have weighed in on DXCM. TheStreet cut DexCom from a “b-” rating to a “c” rating in a report on Thursday, April 29th. Atlantic Securities started coverage on DexCom in a report on Wednesday, April 21st. They issued an “overweight” rating and a $438.00 target price for the company. Morgan Stanley boosted their price target on DexCom from $402.00 to $410.00 and gave the stock an “equal weight” rating in a research report on Friday, February 12th. Canaccord Genuity boosted their price target on DexCom from $445.00 to $455.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Piper Sandler boosted their price target on DexCom from $465.00 to $500.00 and gave the stock an “overweight” rating in a research report on Friday, January 29th.
Shares of DexCom stock traded down $9.15 during trading on Thursday, hitting $371.42. 42,337 shares of the company’s stock traded hands, compared to its average volume of 830,056. DexCom has a 1 year low of $305.63 and a 1 year high of $456.23. The company has a debt-to-equity ratio of 1.10, a current ratio of 6.39 and a quick ratio of 6.00. The stock has a market capitalization of $35.92 billion, a P/E ratio of 151.60, a PEG ratio of 6.15 and a beta of 0.86. The business has a 50-day simple moving average of $377.84 and a 200-day simple moving average of $368.81.
DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, April 29th. The medical device company reported $0.33 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.31 by $0.02. DexCom had a return on equity of 27.29% and a net margin of 12.69%. On average, equities analysts predict that DexCom will post 3.07 earnings per share for the current fiscal year.
In other news, Director Nicholas Augustinos sold 1,875 shares of the firm’s stock in a transaction on Tuesday, February 16th. The stock was sold at an average price of $412.03, for a total transaction of $772,556.25. Following the completion of the transaction, the director now directly owns 806 shares in the company, valued at $332,096.18. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Patrick Michael Murphy sold 500 shares of the firm’s stock in a transaction on Monday, April 26th. The stock was sold at an average price of $415.83, for a total value of $207,915.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 34,192 shares of company stock valued at $12,681,786. 0.69% of the stock is owned by insiders.
A number of large investors have recently added to or reduced their stakes in the stock. Cowen AND Company LLC purchased a new position in DexCom in the first quarter valued at $1,283,000. Envestnet Asset Management Inc. boosted its holdings in DexCom by 31.9% in the first quarter. Envestnet Asset Management Inc. now owns 122,474 shares of the medical device company’s stock valued at $44,016,000 after purchasing an additional 29,615 shares during the period. Oak Ridge Investments LLC boosted its holdings in DexCom by 973.4% in the first quarter. Oak Ridge Investments LLC now owns 29,938 shares of the medical device company’s stock valued at $10,759,000 after purchasing an additional 27,149 shares during the period. GVO Asset Management Ltd purchased a new position in DexCom in the first quarter valued at $48,000. Finally, Alamar Capital Management LLC boosted its holdings in DexCom by 11.9% in the first quarter. Alamar Capital Management LLC now owns 7,523 shares of the medical device company’s stock valued at $2,704,000 after purchasing an additional 798 shares during the period. Hedge funds and other institutional investors own 94.06% of the company’s stock.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system.
Read More: New Google Finance Tool and Screening Stocks
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.